Outset Medical, Inc. (NASDAQ:OM) Short Interest Down 13.6% in February

Outset Medical, Inc. (NASDAQ:OM) was the recipient of a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 1,915,455 shares, a drop of 13.6% from the February 12th total of 2,217,364 shares. Based on an average trading volume of 247,824 shares, the short-interest ratio is currently 7.7 days. Currently, 10.7% of the shares of the company are sold short. Currently, 10.7% of the shares of the company are sold short. Based on an average trading volume of 247,824 shares, the short-interest ratio is currently 7.7 days.

Outset Medical Price Performance

NASDAQ OM traded down $0.19 on Wednesday, reaching $3.42. The company’s stock had a trading volume of 55,652 shares, compared to its average volume of 852,298. Outset Medical has a twelve month low of $3.00 and a twelve month high of $21.98. The company has a debt-to-equity ratio of 0.76, a quick ratio of 5.40 and a current ratio of 6.67. The firm’s 50 day moving average is $4.23 and its two-hundred day moving average is $7.71. The stock has a market cap of $62.65 million, a PE ratio of -0.51 and a beta of 2.13.

Analyst Ratings Changes

OM has been the topic of a number of research analyst reports. Royal Bank Of Canada reissued a “sector perform” rating and set a $7.00 price target on shares of Outset Medical in a report on Wednesday, December 17th. BTIG Research lowered their target price on shares of Outset Medical from $17.00 to $15.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Wall Street Zen downgraded shares of Outset Medical from a “hold” rating to a “sell” rating in a research report on Sunday, February 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 29th. Finally, Stifel Nicolaus lowered their price objective on shares of Outset Medical from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Wednesday, January 7th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Insider Activity

In related news, EVP Marc Nash sold 5,375 shares of the firm’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $27,520.00. Following the sale, the executive vice president owned 42,785 shares of the company’s stock, valued at approximately $219,059.20. This trade represents a 11.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Leslie Trigg sold 11,794 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $5.12, for a total value of $60,385.28. Following the completion of the sale, the chief executive officer directly owned 107,823 shares in the company, valued at $552,053.76. This represents a 9.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 40,910 shares of company stock valued at $193,040. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc bought a new stake in shares of Outset Medical during the 2nd quarter worth $34,000. Ameritas Investment Partners Inc. acquired a new position in shares of Outset Medical in the 2nd quarter valued at $35,000. BNP Paribas Financial Markets boosted its position in shares of Outset Medical by 7,013.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new position in Outset Medical in the 2nd quarter worth about $78,000. Finally, New York State Common Retirement Fund acquired a new stake in Outset Medical during the 2nd quarter worth about $108,000.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.